GlassScriptPhysician profile
Brandi L Parlee
NPI 1447792973
$1,951.73
in general payments reported to CMS, 2019-2025
30 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $874 · 2023: $445 · 2024: $253 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $372.79 | 2021-2023 | Wegovy |
| Abbvie INC. | $278.75 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.65 | 2023-2025 | Relistor |
| Lilly USA, LLC | $173.48 | 2021-2023 | Amyvid, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $70.38 | 2022 | |
| Collegium Pharmaceutical, INC. | $67.64 | 2023-2024 | Belbuca |
| Merz Pharmaceuticals, LLC | $63.95 | 2023-2024 | Xeomin |
| Sk Life Science, INC. | $62.74 | 2023 | |
| Ucb, INC. | $61.21 | 2023 | Briviact |
| Corcept Therapeutics | $56.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.11 | 2021 | |
| Depuy Synthes Sales INC. | $45.38 | 2024 | Monovisc, Orthovisc |
| Azurity Pharmaceuticals, INC. | $43.93 | 2023-2024 | Horizant, Horizant |
| Astrazeneca Pharmaceuticals LP | $36.90 | 2022 | |
| Averitas Pharma INC. | $32.62 | 2023 | Qutenza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $28.46 | 2024 | Movantik |
| Biohaven Pharmaceutical Holding Company LTD. | $25.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.30 | 2022 | |
| Grifols USA, LLC | $22.80 | 2023 | Gamunex-C |
| Xeris Pharmaceuticals, INC. | $22.69 | 2022 | |
| Medela LLC | $20.11 | 2022 | |
| Tanabe Pharma America, INC. | $17.07 | 2023 | |
| Exact Sciences Corporation | $16.97 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $16.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.37 | 2022 | |
| Esperion Therapeutics, INC. | $15.81 | 2021 | |
| Teleflex LLC | $12.73 | 2021 | |
| Currax Pharmaceuticals LLC | $12.46 | 2022 | |
| Bausch Health US, LLC | $12.14 | 2021 | |
| Pfizer INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Parlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.